Skip to main navigation

About
R&D
Pipeline
Investors & Media
Careers

Investors & Media

Overview
News
Events & Presentations
Stock Information
- Stock Quote & Chart
- Analyst Coverage
SEC Filings
Corporate Governance
Investor Resources
- FAQs
- Investor Contact

News

Year

February 23, 2020

NGM Bio to Host Conference Call to Discuss Preliminary Topline Results, Including Histology Data, from 24-Week Phase 2 Study of Aldafermin in Patients with NASH

February 11, 2020

NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS)

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 5 - 6 of 6

Stock Quote

Contact Information

Investor Relations:
ir@ngmbio.com

Media Relations:
media@ngmbio.com

Toolkit

© 2020 NGM Biopharmaceuticals, Inc..

All Rights Reserved.

Privacy Policy.

Top